Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018

Published:2020-09-12 Issue:4 Volume:148 Page:868-875
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Board Ruth¹,Smittenaar Rebecca²^ORCID,Lawton Sarah²,Liu Hanhua²,Juwa Bukky²,Chao David³,Corrie Pippa⁴

Affiliation:

1. Department of Oncology Lancashire Teaching Hospitals NHS Trust Preston UK

2. National Cancer Registration and Analysis Service, Health Improvement Directorate Public Health England London UK

3. Department of Oncology Royal Free London NHS Foundation Trust London UK

4. Department of Oncology Cambridge University Hospitals NHS Foundation Trust Cambridge UK

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33266

Reference18 articles.

1. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

2. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

3. Pembrolizumab versus Ipilimumab in Advanced Melanoma

4. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

5. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab;npj Precision Oncology;2024-07-19

2. Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study;Frontiers in Oncology;2024-05-31

3. Blood Vitamin C Levels of Patients Receiving Immunotherapy and Relationship to Monocyte Subtype and Epigenetic Modification;Epigenomes;2024-04-30

4. Immune-related adverse event in the emergency department: methodology of the immune-related emergency disposition index (IrEDi);Emergency Cancer Care;2024-01-29

5. Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies;European Journal of Cancer;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3